Epilepsy is one of the most common neurological chronic disorders, with an estimated
prevalence of 0. 5–1%. Currently, treatment options for epilepsy are predominantly based on …

Rationale Cannabidiol (CBD) products lacking regulatory approval are being used to self-
treat a myriad of conditions and for their unsubstantiated health benefits. The scientific …

Cannabidiol (CBD), a major non-psychoactive phytocannabinoid in cannabis, is an effective
treatment for some forms of epilepsy and pain. At high concentrations, CBD interacts with a …

Background: Currently, there is a great interest in the potential medical use of cannabidiol
(CBD), a non-intoxicating cannabinoid. Productive pharmacological research on CBD …

Background Cannabidiol has been used for treatment-resistant seizures in patients with
severe early-onset epilepsy. We investigated the efficacy and safety of cannabidiol added to …

Background: Cannabidiol is being pursued as a therapeutic treatment for multiple
conditions, usually by oral delivery. Animal studies suggest oral bioavailability is low, but …

Summary Background Patients with Lennox-Gastaut syndrome, a rare, severe form of
epileptic encephalopathy, are frequently treatment resistant to available medications. No …

Cannabidiol (CBD) is being investigated as a treatment for several medical disorders but
there is uncertainty about its safety. We conducted the first systematic review and meta …

Background A formal single ascending and multiple dose pharmacokinetic (PK) trial of
cannabidiol (CBD) oral solution was required to determine the safety and tolerability of CBD …

The developmental and epileptic encephalopathies encompass a group of rare syndromes
characterised by severe drug-resistant epilepsy with onset in childhood and significant …